Boston Biomedical, Inc. is a leading developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. As a fully integrated oncology drug research and development company, Boston Biomedical, Inc. has established a track record of accomplishments, including advancing the research and development of multiple compounds and clinical programs. The company’s range of expertise includes drug discovery, external innovation partnerships, medicinal chemistry, preclinical development, pharmacology, pharmaceutical development, CMC (chemistry, manufacturing, and control), global clinical trials, regulatory affairs and commercialization. Headquartered in Cambridge, Massachusetts, Boston Biomedical, Inc. has created a unique corporate environment, leveraging its innovation-driven culture, scientific leadership, and drug development expertise to advance the development of novel therapeutics for patients with cancer. Visit https://www.bostonbiomedical.com/careers/ for more information. Boston Biomedical, Inc. is indirectly and wholly owned by Sumitomo Dainippon Pharma Co., Ltd., a pharmaceutical company based in Japan. In 2017, Sumitomo Dainippon Pharma acquired Tolero Pharmaceuticals, a U.S.-based biotechnology company specializing in research and development of therapeutic agents in the areas of oncology and hematological disorders. This acquisition expanded Sumitomo Dainippon Pharma’s global oncology and hematology portfolios. Together, the companies – Sumitomo Dainippon Pharma Co., Ltd., Boston Biomedical and Tolero Pharmaceuticals – work to expedite drug discovery, development and commercialization of innovative treatments for cancer. This collaboration harnesses the expertise of each organization with the goal of significantly improving patient outcomes.